User banner image
User avatar
  • admin

Posts

/C O R R E C T I O N — Appian/

In the news release, NSW Community Services Workers Now Accessing Long Service Leave Across Multiple Employers on Appian, issued 22-Jul-2026 by Appian over PR Newswire,...

OneConstruction Group Limited Announces Annual Financial Results for the Fiscal Year Ended March 31, 2026

OneConstruction Group Limited(NASDAQ: ONEG) NEW YORK, July 24, 2026 /PRNewswire/ — OneConstruction Group Limited (“OneConstruction Group” or “ONEG”), a Cayman Islands exempted company with limited...

Fly-E Group, Inc. Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)

NEW YORK, July 24,2026 /PRNewswire/ — Fly-E Group, Inc. (Nasdaq: FLYE) (“Fly-E” or the “Company”), an electric vehicle company engaged in designing, installing, selling, and renting...

Bread Financial Provides Performance Update for June 2026

COLUMBUS, Ohio, July 23, 2026 (GLOBE NEWSWIRE) — Bread Financial Holdings, Inc. (NYSE: BFH), a tech-forward financial services company that provides simple, personalized payment, lending, and...

Bread Financial Reports Second Quarter 2026 Results

COLUMBUS, Ohio, July 23, 2026 (GLOBE NEWSWIRE) — Bread Financial® Holdings, Inc. (NYSE: BFH), a tech-forward financial services company that provides simple, flexible payment, lending and saving...

Ardelyx to Report Second Quarter 2026 Financial Results on August 6, 2026

Conference call scheduled for 4:30 p.m. Eastern Time WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) — Ardelyx, Inc. (Nasdaq: ARDX) (“Ardelyx” or the “Company”), a...

Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026

CLEARWATER, Fla., July 23, 2026 (GLOBE NEWSWIRE) — Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold...

iMDx GraftAssure Assay Guides Use of Potentially Kidney-Graft-Saving Drug in New Lancet Group Publication

Study published by Lancet Regional Health helps doctors manage new class of drugs for kidney transplant patients suffering organ rejection Serial monitoring of patients through...

Bone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 Priorities

Strengthened capital position supports continued advancement of NB1 clinical development, manufacturing readiness and intellectual property initiatives through Q2 2027 BURLINGTON, Mass, July 23, 2026 (GLOBE...

Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH

WILMINGTON, Del., July 23, 2026 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial...